Proteome Sciences PLC Grant of Options and PDMR/director shareholdings (5531C)
12 October 2022 - 5:00PM
UK Regulatory
TIDMPRM
RNS Number : 5531C
Proteome Sciences PLC
12 October 2022
12 October 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Grant of Options and PDMR/director shareholdings
Proteome Sciences announces the grant of options over new
ordinary shares of 1p each in the Company ("Ordinary Shares") under
the Company's share option schemes ("Options"). A total of
3,000,000 Options were yesterday issued to two directors of the
Company.
Details of the Options granted to directors are outlined in the
table below:
Name of Director Number of Options Total number
Granted of options now
held
Dr Ian Pike 1,500,000 4,000,000
------------------ ----------------
Mr Richard Dennis 1,500,000 4,000,000
------------------ ----------------
The Options are exercisable at the closing price of the
Company's Ordinary Shares' yesterday, being 4.3 pence per Option.
For Dr Ian Pike and Mr Richard Dennis , the Options will vest in
three tranches as to 500,000 on 11 October 2023, 500,000 on 11
October 2024 and 500,000 on 11 October 2025. Options have also been
awarded to other employees totaling 2,520,000. Each Option is
exercisable into one Ordinary Share and once vested, can be
exercised up until the 10th anniversary of yesterday's date.
The Options granted yesterday represent approximately 1.87 per
cent of the Company's current issued share capital. In total
20,534,000 Options are now outstanding, representing approximately
6.96 per cent of the Company's current issued share capital.
Further details and the information required in accordance with
the requirements of Article 19(3) of the Market Abuse Regulation No
596/2014 (as retained and applicable in the UK pursuant to section
3 of the European Union (Withdrawal) Act 2018) ("UK MAR") are set
out at the end of this announcement.
For further information:
Proteome Sciences plc Tel: +44 (0)20 7043
Dr Mariola Soehngen, Chief Executive Officer 2116
Abdelghani Omari, Chief Financial Officer
Dr Ian Pike, Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Tel: +44 (0) 20 3328
Adviser & Broker) 5656
John Depasquale / Jeremy Porter
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in Cobham, UK, with laboratory
facilities in Frankfurt, Germany.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
The below notification is made in accordance with the
requirements of UK MAR.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Ian Pike
----------------------------------------- -----------------------------------
Reason for the notification
2.
------------------------------------------------------------------------------
a) Position/status: Chief Scientific Officer
----------------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- -----------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- -----------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- -----------------------------------
Details of the transaction(s): section to be repeated for
4. (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- -----------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
GBP0.043 1,500,000
----------
----------------------------------------- -----------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
GBP0.043 1,500,000
* Price: ----------
----------------------------------------- -----------------------------------
e) Date of the transaction: 11 October 2022
----------------------------------------- -----------------------------------
f) Place of the transaction: N/A
----------------------------------------- -----------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Richard Dennis
----------------------------------------- -----------------------------------
Reason for the notification
2.
------------------------------------------------------------------------------
a) Position/status: Chief Commercial Officer
----------------------------------------- -----------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- -----------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- -----------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- -----------------------------------
Details of the transaction(s): section to be repeated for
4. (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p
type of instrument: nominal value
Identification code: GB0003104196
----------------------------------------- -----------------------------------
b) Nature of the transaction: Grant of options under
the Proteome Sciences
plc 2011 Long Term Share
Incentive Plan to acquire
ordinary shares of 1p
each in Proteome Sciences
plc
----------------------------------------- -----------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
GBP0.043 1,500,000
----------
----------------------------------------- -----------------------------------
d) Aggregated information: Single transaction as
* Aggregated volume: in c) above Average Volume(s)
Price
GBP0.043 1,500,000
Price: ----------
----------------------------------------- -----------------------------------
e) Date of the transaction: 11 October 2022
----------------------------------------- -----------------------------------
f) Place of the transaction: N/A
----------------------------------------- -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDFLFFLBLXFBV
(END) Dow Jones Newswires
October 12, 2022 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
